My Approach to the Patient With Familial Hypercholesterolemia

Mayo Clinic Proceedings

Volumn 91, Issue 6, 2016, Pages 770-786

  Safarova, Maya S ^a   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOMITAPIDE; MIPOMERSEN; PITAVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ARTICLE; AWARENESS; CLINICAL EVALUATION; CLINICAL EXAMINATION; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE CONTROL; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIVER TRANSPLANTATION; MEDICAL HISTORY; PATHOGENESIS; PORTOCAVAL SHUNT; PREGNANT WOMAN; PREVALENCE; SCREENING TEST; TREATMENT OUTCOME; XANTHOMA; ADOLESCENT; ADULT; BLOOD; CARDIOVASCULAR DISEASE; CASE REPORT; CHILD; EARLY DIAGNOSIS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MASS SCREENING; MIDDLE AGED; ONSET AGE; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROCEDURES; SEX RATIO; STANDARDS;

ADOLESCENT; ADULT; AGE OF ONSET; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, HDL; EARLY DIAGNOSIS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIVER TRANSPLANTATION; MALE; MASS SCREENING; MIDDLE AGED; PORTACAVAL SHUNT, SURGICAL; PREVALENCE; PRIMARY PREVENTION; SEX DISTRIBUTION; TRIGLYCERIDES;

EID: 84982105651     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.04.013     Document Type: Article

References (135)

1. 1 Ding, K., Kullo, I.J., Evolutionary genetics of coronary heart disease. Circulation 119:3 (2009), 459–467.
2. 2 Ding, K., Kullo, I.J., Molecular population genetics of PCSK9: a signature of recent positive selection. Pharmacogenet Genomics 18:3 (2008), 169–179.
3. 3 Ding, K., McDonough, S.J., Kullo, I.J., Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS One, 2(10), 2007, e1098.
4. 4 Muller, C., Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 89 (1938), 75–84.
5. 5 Muller, C., Angina pectoris in hereditary xanthomatosis. Arch Intern Med 64 (1939), 675–700.
6. 6 Khachadurian, A.K., The inheritance of essential familial hypercholesterolemia. Am J Med 37 (1964), 402–407.
7. 7 Fredrickson, D.S., Levy, R.I., Lees, R.S., Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 276:5 (1967), 273–281 contd.
8. 8 Goldstein, J.L., Brown, M.S., The LDL receptor. Arterioscler Thromb Vasc Biol 29:4 (2009), 431–438.
9. 9 Russell, D.W., Yamamoto, T., Schneider, W.J., Slaughter, C.J., Brown, M.S., Goldstein, J.L., cDNA cloning of the bovine low density lipoprotein receptor: feedback regulation of a receptor mRNA. Proc Natl Acad Sci U S A 80:24 (1983), 7501–7505.
10. 10 Sjouke, B., Kusters, D.M., Kindt, I., et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 36:9 (2015), 560–565.
11. 11 Marduel, M., Ouguerram, K., Serre, V., et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 34:1 (2013), 83–87.
12. 12 Awan, Z., Choi, H.Y., Stitziel, N., et al. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 231:2 (2013), 218–222.
13. 13 Ferrieres, J., Sing, C.F., Roy, M., Davignon, J., Lussier-Cacan, S., Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler Thromb 14:10 (1994), 1553–1560.
14. 14 Fouchier, S.W., Dallinga-Thie, G.M., Meijers, J.C., et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 115:6 (2014), 552–555.
15. 15 Braenne, I., Kleinecke, M., Reiz, B., et al. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet 24:2 (2016), 191–197.
16. 16 Garcia, C.K., Wilund, K., Arca, M., et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:5520 (2001), 1394–1398.
17. 17 Khera, A.V., Won, H.-H., Peloso, G.M., et al. Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol, 2016 Mar 28 pii: S0735-1097(16)32399-3. doi: 10.1016/j.jacc.2016.03.520.
18. 18 Talmud, P.J., Shah, S., Whittall, R., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 381:9874 (2013), 1293–1301.
19. 19 Futema, M., Shah, S., Cooper, J.A., et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 61:1 (2015), 231–238.
20. 20 Futema, M., Plagnol, V., Li, K., et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 51:8 (2014), 537–544.
21. 21 Cuchel, M., Bruckert, E., Ginsberg, H.N., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management: a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35:32 (2014), 2146–2157.
22. 22 Austin, M.A., Hutter, C.M., Zimmern, R.L., Humphries, S.E., Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160:5 (2004), 421–429.
23. 23 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:45 (2013), 3478–3490a.
24. 24 Hopkins, P.N., Toth, P.P., Ballantyne, C.M., Rader, D.J., Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:3, suppl (2011), S9–S17.
25. 25 Neil, H.A., Hammond, T., Huxley, R., Matthews, D.R., Humphries, S.E., Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ, 321(7254), 2000, 148.
26. 26 de Ferranti, S.D., Rodday, A.M., Mendelson, M.M., Wong, J.B., Leslie, L.K., Sheldrick, R.C., Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 133:11 (2016), 1067–1072.
27. 27 Weng, S.F., Kai, J., Andrew Neil, H., Humphries, S.E., Qureshi, N., Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 238:2 (2015), 336–343.
28. 28 Benn, M., Watts, G.F., Tybjaerg-Hansen, A., Nordestgaard, B.G., Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 97:11 (2012), 3956–3964.
29. 29 Lahtinen, A.M., Havulinna, A.S., Jula, A., Salomaa, V., Kontula, K., Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population. Atherosclerosis 238:1 (2015), 64–69.
30. 30 Shi, Z., Zhou, M., Yuan, B., et al. Iron intake and body iron stores, anaemia and risk of hyperglycaemia among Chinese adults: the prospective Jiangsu Nutrition Study (JIN). Public Health Nutr 13:9 (2010), 1319–1327.
31. 31 Dunstan, D.W., Zimmet, P.Z., Welborn, T.A., et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab): methods and response rates. Diabetes Res Clin Pract 57:2 (2002), 119–129.
32. 32 Watts, G.F., Shaw, J.E., Pang, J., Magliano, D.J., Jennings, G.L., Carrington, M.J., Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol 185 (2015), 69–71.
33. 33 The Medway Clinical Commissioning Group. Systematically Identifying Familial Hypercholesterolemia in Primary Care: Interim Report for HEART UK Conference, July 2-4 2014. Berkshire, United Kingdom: Heart UK; 2014:1-8.
34. 34 Karpov, Y.A., Kukharchuk, V.V., Boytsov, S.A., et al. Consensus Statement of the Russian National Atherosclerosis Society. Familial hypercholesterolemia in Russia: outstanding issues in diagnosis and management [in Russian]. Ateroskleroz i dislipidemii., 2(19), 2015, 5–16.
35. 35 Miller, P.E., Martin, S.S., Toth, P.P., et al. Screening and advanced lipid phenotyping in familial hypercholesterolemia: the Very Large Database of Lipids Study-17 (VLDL-17). J Clin Lipidol 9:5 (2015), 676–683.
36. 36 Foody, J.M., Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin Cardiol 37:2 (2014), 119–125.
37. 37 O'Brien, E.C., Roe, M.T., Fraulo, E.S., et al. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J 167:3 (2014), 342–349.e17.
38. 38 O'Brien, E.C., DeGoma, E., Moriarty, P., et al. Initial results from the CASCADE-FH registry: cascade screening for awareness and detection of familial hypercholesterolemia. J Am Coll Cardiol, 65, 2015 doi:10.1016/S0735-1097(1015)61372-61379.
39. 39 deGoma, E.M., Ahmad, Z.S., O'Brien, E.C., et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH Registry. Circ Cardiovasc Genet, 2016 Mar 24 pii: CIRCGENETICS.116.001381.
40. 40 De Backer, G., Besseling, J., Chapman, J., et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 241:1 (2015), 169–175.
41. 41 Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia, part 1: executive summary. J Clin Lipidol 8:5 (2014), 473–488.
42. 42 Jansen, A.C., van Aalst-Cohen, E.S., Tanck, M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 256:6 (2004), 482–490.
43. 43 Besseling, J., Kindt, I., Hof, M., Kastelein, J.J., Hutten, B.A., Hovingh, G.K., Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 233:1 (2014), 219–223.
44. 44 Horton, J.D., Cohen, J.C., Hobbs, H.H., PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50:suppl (2009), S172–S177.
45. 45 Huijgen, R., Hutten, B.A., Kindt, I., Vissers, M.N., Kastelein, J.J., Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet 5:3 (2012), 354–359.
46. 46 Hadfield, S.G., Horara, S., Starr, B.J., et al. Are patients with familial hypercholesterolaemia well managed in lipid clinics? an audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Ann Clin Biochem 45:pt 2 (2008), 199–205.
47. 47 Pimstone, S.N., Sun, X.M., du Souich, C., Frohlich, J.J., Hayden, M.R., Soutar, A.K., Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 18:2 (1998), 309–315.
48. 48 Pang, J., Poulter, E.B., Bell, D.A., et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol 9:5 (2015), 703–708.
49. 49 Marks, D., Thorogood, M., Neil, H.A., Humphries, S.E., A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168 (2003), 1–14.
50. 50 Pereira, C., Miname, M.H., Makdisse, M.R., et al. Peripheral arterial disease in heterozygous familial hypercholesterolemia. Atherosclerosis 242:1 (2015), 174–178.
51. 51 Hutter, C.M., Austin, M.A., Humphries, S.E., Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am J Epidemiol 160:5 (2004), 430–435.
52. 52 Junyent, M., Gilabert, R., Zambon, D., et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol 25:10 (2005), 2203–2208.
53. 53 Damgaard, D., Larsen, M.L., Nissen, P.H., et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180:1 (2005), 155–160.
54. 54 Vongpromek, R., Bos, S., Ten Kate, G.J., et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med 278:2 (2015), 166–173.
55. 55 Nozue, T., Kawashiri, M.A., Higashikata, T., et al. Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 13:6 (2006), 323–328.
56. 56 ten Kate, G.J., Bos, S., Dedic, A., et al. Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factors. J Am Coll Cardiol 66:24 (2015), 2687–2695.
57. 57 Otto, C.M., Prendergast, B., Aortic-valve stenosis: from patients at risk to severe valve obstruction. N Engl J Med 371:8 (2014), 744–756.
58. 58 Gidding, S.S., Ann Champagne, M., de Ferranti, S.D., et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 132:22 (2015), 2167–2192.
59. 59 Haralambos, K., Whatley, S.D., Edwards, R., et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 240:1 (2015), 190–196.
60. 60 Harada-Shiba, M., Arai, H., Oikawa, S., et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 19:12 (2012), 1043–1060.
61. 61 Goldman, L., Goldman, P.A., Williams, L.W., Weinstein, M.C., Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 72:10 (1993), 75D–79D.
62. 62 Starr, B., Hadfield, S.G., Hutten, B.A., et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 46:6 (2008), 791–803.
63. 63 Medeiros, A.M., Alves, A.C., Bourbon, M., Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. Genet Med 18:4 (2016), 316–324.
64. 64 Watts, G.F., Gidding, S., Wierzbicki, A.S., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 171:3 (2014), 309–325.
65. 65 Hardcastle, S.J., Legge, E., Laundy, C.S., et al. Patients’ perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int J Behav Med 22:1 (2015), 92–100.
66. 66 Marteau, T., Senior, V., Humphries, S.E., et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A 128A:3 (2004), 285–293.
67. 67 Homsma, S.J., Huijgen, R., Middeldorp, S., Sijbrands, E.J., Kastelein, J.J., Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Eur J Hum Genet 16:1 (2008), 14–17.
68. 68 Huijgen, R., Homsma, S.J., Hutten, B.A., et al. Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study. Eur J Hum Genet 20:7 (2012), 722–728.
69. 69 Centers for Disease Control and Prevention. Genomics implementation. More detailed information on key tier 1 applications: familial hypercholesterolemia. http://www.cdc.gov/genomics/implementation/toolkit/fh_1.htm. Accessed October 5, 2015.
70. 70 de Sauvage Nolting, P.R., Defesche, J.C., Buirma, R.J., Hutten, B.A., Lansberg, P.J., Kastelein, J.J., Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 253:2 (2003), 161–168.
71. 71 Leitersdorf, E., Friedlander, Y., Bard, J.M., Fruchart, J.C., Eisenberg, S., Stein, Y., Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia. J Lipid Res 32:9 (1991), 1513–1519.
72. 72 Kraft, H.G., Lingenhel, A., Raal, F.J., Hohenegger, M., Utermann, G., Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:2 (2000), 522–528.
73. 73 van Deventer, H.E., Miller, W.G., Myers, G.L., et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem 57:3 (2011), 490–501.
74. 74 Meeusen, J.W., Snozek, C.L., Baumann, N.A., Jaffe, A.S., Saenger, A.K., Reliability of calculated low-density lipoprotein cholesterol. Am J Cardiol 116:4 (2015), 538–540.
75. 75 Kullo, I.J., Malik, A.R., Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol 49:13 (2007), 1413–1426.
76. 76 Neefjes, L.A., Ten Kate, G.J., Rossi, A., et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart 97:14 (2011), 1151–1157.
77. 77 Shipman, K.E., Higginson, E.J., Haddon, A.L., Wong, M.Y., Labib, M.Z., The use of CT coronary calcium score in asymptomatic patients with familial hypercholesterolaemia. Br J Diabetes Vasc Dis 5 (2015), 1–3.
78. 78 Kusters, D.M., Avis, H.J., de Groot, E., et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 312:10 (2014), 1055–1057.
79. 79 Robinson, J.G., Goldberg, A.C., National Lipid Association Expert Panel on Familial Hypercholesterolemia. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:3 suppl (2011), S18–S29.
80. 80 Green, R.F., Dotson, W.D., Bowen, S, et al. Genomics in public health: perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC). Healthcare (Basel) 3:3 (2015), 830–837.
81. 81 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:25, pt B (2014), 2889–2934.
82. 82 Starc, T.J., Belamarich, P.F., Shea, S., et al. Family history fails to identify many children with severe hypercholesterolemia. Am J Dis Child 145:1 (1991), 61–64.
83. 83 Klancar, G., Groselj, U., Kovac, J., et al. Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol 66:11 (2015), 1250–1257.
84. 84 Goldberg, A.C., Hopkins, P.N., Toth, P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:3, suppl (2011), S1–S8.
85. 85 Wald, D.S., Bestwick, J.P., Wald, N.J., Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ, 335(7620), 2007, 599.
86. 86 Daniels, S.R., Screening for familial hypercholesterolemia: what is the most effective strategy?. Nat Clin Pract Cardiovasc Med 5:3 (2008), 130–131.
87. 87 Margolis, K.L., Greenspan, L.C., Trower, N.K., et al. Lipid screening in children and adolescents in community practice: 2007 to 2010. Circ Cardiovasc Qual Outcomes 7:5 (2014), 718–726.
88. 88 Wald, D.S., Kasturiratne, A., Godoy, A., et al. Child-parent screening for familial hypercholesterolemia. J Pediatr 159:5 (2011), 865–867.
89. 89 Bell, D.A., Bender, R., Hooper, A.J., et al. Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clin Chim Acta 422 (2013), 21–25.
90. 90 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128:suppl 5 (2011), S213–S256.
91. 91 Ademi, Z., Watts, G.F., Juniper, A., Liew, D., A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 167:6 (2013), 2391–2396.
92. 92 Umans-Eckenhausen, M.A., Defesche, J.C., Sijbrands, E.J., Scheerder, R.L., Kastelein, J.J., Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357:9251 (2001), 165–168.
93. 93 DeMott, K., Nherera, L., Shaw, E.J., et al. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: The Identification and Management of Adults and Children With Familial Hypercholesterolaemia. 2008, National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, England.
94. 94 Watts, G.F., Sullivan, D.R., Poplawski, N., et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 12:2 (2011), 221–263.
95. 95 Versmissen, J., Oosterveer, D.M., Yazdanpanah, M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
96. 96 Thompson, G.R., Seed, M., Naoumova, R.P., et al. Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis 243:1 (2015), 328–333.
97. 97 Reiner, Z., A comparison of European and US guidelines for familial hypercholesterolaemia. Curr Opin Lipidol 26:3 (2015), 215–220.
98. 98 Genest, J., Hegele, R.A., Bergeron, J., et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 30:12 (2014), 1471–1481.
99. 99 National Institutet for Health and Care Excellence. Familial hypercholesterolaemia: identification and management. 2008. https://www.nice.org.uk/guidance/cg71. Accessed September 1, 2015.
100. 100 Pisciotta, L., Fasano, T., Bellocchio, A., et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 194:2 (2007), e116–e122.
101. 101 Nozue, T., Michishita, I., Mizuguchi, I., Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 17:1 (2010), 37–44.
102. 102 Knopp, R.H., Gitter, H., Truitt, T., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24:8 (2003), 729–741.
103. 103 Davidson, M.H., A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol 5:2 (2011), 76–81.
104. 104 Robinson, J.G., Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm 19:2 (2013), 139–149.
105. 105 Rader, D.J., Kastelein, J.J., Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129:9 (2014), 1022–1032.
106. 106 Kastelein, J.J., Akdim, F., Stroes, E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358:14 (2008), 1431–1443.
107. 107 Visser, M.E., Akdim, F., Tribble, D.L., et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 51:5 (2010), 1057–1062.
108. 108 Marais, A.D., Raal, F.J., Stein, E.A., et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197:1 (2008), 400–406.
109. 109 Lavigne, P.M., Karas, R.H., The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 61:4 (2013), 440–446.
110. 110 Landray, M.J., Haynes, R., Hopewell, J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371:3 (2014), 203–212.
111. 111 Hou, R., Goldberg, A.C., Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 38:1 (2009), 79–97.
112. 112 Davidson, M., The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther 35:8 (2013), 1247–1252.
113. 113 Kastelein, J.J., Ginsberg, H.N., Langslet, G., et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 36:43 (2015), 2996–3003.
114. 114 Raal, F.J., Stein, E.A., Dufour, R., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:9965 (2015), 331–340.
115. 115 Raal, F.J., Honarpour, N., Blom, D.J., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385:9965 (2015), 341–350.
116. 116 Navarese, E.P., Kolodziejczak, M., Schulze, V., et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 163:1 (2015), 40–51.
117. 117 Raal, F.J., Santos, R.D., Blom, D.J., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:9719 (2010), 998–1006.
118. 118 Cuchel, M., Meagher, E.A., du Toit Theron, H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381:9860 (2013), 40–46.
119. 119 de Gennes, J.L., Touraine, R., Maunand, B., Truffert, J., Laudat, P., Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case: trial of plasmapheresis and heroic treatment. [in French] Bull Mem Soc Med Hop Paris 118:15 (1967), 1377–1402.
120. 120 Schwartz, J., Winters, J.L., Padmanabhan, A., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:3 (2013), 145–284.
121. 121 Malatack, J.J., Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late. Pediatr Transplant 15:2 (2011), 123–125.
122. 122 Wiegman, A., Gidding, S.S., Watts, G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 36:36 (2015), 2425–2437.
123. 123 Noji, Y., Higashikata, T., Inazu, A., et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163:1 (2002), 157–164.
124. 124 Harada-Shiba, M., Arisaka, O., Ohtake, A., Okada, T., Suganami, H., Efficacy and safety of pitavastatin in Japanese male children with familial hypercholesterolemia. J Atheroscler Thromb 23:1 (2016), 48–55.
125. 125 Wiegman, A., Hutten, B.A., de Groot, E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292:3 (2004), 331–337.
126. 126 Kusters, D.M., Caceres, M., Coll, M., et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr 166:6 (2015), 1377–1384.e1-3.
127. 127 Stein, E.A., Marais, A.D., Szamosi, T., et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 156:2 (2010), 231–236.e1-3.
128. 128 Coker, M., Ucar, S.K., Simsek, D.G., Darcan, S., Bak, M., Can, S., Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Ther Apher Dial 13:2 (2009), 121–128.
129. 129 Uauy, R., Zwiener, R.J., Phillips, M.J., Petruska, M.L., Bilheimer, D.W., Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis. J Pediatr 120:6 (1992), 892–898.
130. 130 Zwiener, R.J., Uauy, R., Petruska, M.L., Huet, B.A., Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr 126:5, pt 1 (1995), 728–735.
131. 131 Palcoux, J.B., Atassi-Dumont, M., Lefevre, P., et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 12:3 (2008), 195–201.
132. 132 Fahed, A.C., Nassar, A.H., Pregnancy in a woman with homozygous familial hypercholesterolemia not on low-density lipoprotein apheresis. AJP Rep 2:1 (2012), 33–36.
133. 133 Rutherford, J.D., Maternal heterozygous familial hypercholesterolemia and its consequences for mother and child. Circulation 124:15 (2011), 1599–1601.
134. 134 Kroon, A.A., Swinkels, D.W., van Dongen, P.W., Stalenhoef, A.F., Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism 43:9 (1994), 1164–1170.
135. 135 Schofield, J., Bhatnagar, D., The impact of gestational hypercholesterolaemia on origins of disease. Atherosclerosis 243:2 (2015), 652–653.